Q-omics provides the consensus-scored GTF2IRD2B profile across patient tissues and cancer cell-line models. GTF2IRD2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GTF2IRD2B is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, GTF2IRD2B RNA expression shows 20,319 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, THCA, and UVM as cancer lineages where GTF2IRD2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2IRD2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2IRD2B survival associations across molecular data types. GTF2IRD2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2IRD2B RNA expression–survival associations across cancer types. High GTF2IRD2B expression shows unfavorable associations in LGG and ACC, but favorable associations in BLCA, BRCA, MESO and KIRP. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GTF2IRD2B RNA expression.
This table summarizes GTF2IRD2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GTF2IRD2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2IRD2B shows lower tumor expression in THCA, BLCA, UCEC, LUSC, LUAD and KICH. The THCA box plot shows higher GTF2IRD2B RNA expression in normal versus tumor tissue (log2 FC = −0.843, t-test p < 0.001).
This table shows molecular features associated with GTF2IRD2B in patient tissues and cancer cell lines. In patient samples, GTF2IRD2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2IRD2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
